TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections, Growth, Iron Status and Educational Achievement Among Orang Asli Schoolchildren in Pos Betau, Pahang, Malaysia
Brief Summary: Intestinal parasitic infections, malnutrition and iron deficiency anaemia (IDA) are still considered as public health problems in rural Malaysia especially among Orang Asli children. Despite intermittent control programmes, the prevalence of these problems is still high suggesting the need of other control and interventions measures. This randomized double-blind, placebo-controlled trial was carried out among Orang Asli schoolchildren from Sekolah Kebangsaan Betau in Pos Betau, Pahang (200 km northeast Kuala Lumpur) to investigate the effects of vitamin A supplementation on intestinal parasitic reinfections, growth, iron status and educational achievement.

HYPOTHESES

1. Vitamin A supplementation has a negative effect on intestinal parasitic reinfections and the worm burden of infections among Orang Asli schoolchildren in Pos Betau, Kuala Lipis, Pahang.
2. Vitamin A supplementation has a positive effect on growth (weight and height) among Orang Asli schoolchildren.
3. Vitamin A supplementation is effective in improving serum iron status among Orang Asli schoolchildren.
4. Vitamin A supplementation has a positive effect on cognitive function and educational achievement among Orang Asli schoolchildren.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections, Growth, Iron Status and Educational Achievement Among Orang Asli Schoolchildren in Pos Betau, Pahang, Malaysia
Brief Summary: Intestinal parasitic infections, malnutrition and iron deficiency anaemia (IDA) are still considered as public health problems in rural Malaysia especially among Orang Asli children. Despite intermittent control programmes, the prevalence of these problems is still high suggesting the need of other control and interventions measures. This randomized double-blind, placebo-controlled trial was carried out among Orang Asli schoolchildren from Sekolah Kebangsaan Betau in Pos Betau, Pahang (200 km northeast Kuala Lumpur) to investigate the effects of vitamin A supplementation on intestinal parasitic reinfections, growth, iron status and educational achievement.

HYPOTHESES

1. Vitamin A supplementation has a negative effect on intestinal parasitic reinfections and the worm burden of infections among Orang Asli schoolchildren in Pos Betau, Kuala Lipis, Pahang.
2. Vitamin A supplementation has a positive effect on growth (weight and height) among Orang Asli schoolchildren.
3. Vitamin A supplementation is effective in improving serum iron status among Orang Asli schoolchildren.
4. Vitamin A supplementation has a positive effect on cognitive function and educational achievement among Orang Asli schoolchildren.


Options:
A: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Observational Study to Evaluate the Long Term Outcomes of Patients Previously Enrolled in the STRokE DOC ("STRokE DOC Trial (NCT00283868)") Telemedicine Clinical Trial.
Brief Summary: SPECIFIC AIM: The specific aims of this study are to evaluate the long term outcomes of patients previously enrolled in the STRokE DOC ("STRokE DOC Trial (NCT00283868)") telemedicine clinical trial.

AIM 1: Aim 1 is a non- randomized, retrospective, data collection study assessing long term patient outcomes of patients previously enrolled in a telemedicine vs. telephone clinical trial (STRokE DOC Trial ("STRokE DOC Trial (NCT00283868)"); now completed). STRokE DOC-LTO will evaluate, (only for those patients previously enrolled in the original telemedicine vs. telephone clinical research trial), the long term patient outcomes; comparing telemedicine versus telephone-only consultations.


Options:
A: Arm Label: TELEmonitoring intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medication Adherence Support System (MASS) | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Medication Adherence Support System (MASS); Assigned to Arm(s): TELEmonitoring intervention
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: telemedicine program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: telemedicine program; Assigned to Arm(s): Telemedicine
C: Arm Label: Telemedicine; Type: N/A; Interventions: N/A | Arm Label: Telephone; Type: N/A; Interventions: N/A
D: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate
Brief Summary: The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.


Options:
A: N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH, Drug: OROS MPH Tablets | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo Tablets | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: OROS MPH Tablets; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 002
C: Arm Label: Ritalin LA; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA (methylphenidate hydrochloride extended release) | Intervention Type: DRUG; Name: Ritalin LA (methylphenidate hydrochloride extended release); Assigned to Arm(s): Ritalin LA
D: Arm Label: Osmotic-Release Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Osmotic-Release Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Osmotic-Release Methylphenidate; Assigned to Arm(s): Osmotic-Release Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study)
Brief Summary: This DWCIE Study is a prospective cohort study of patients fit to the FDA approved and marketed lotrafilcon A (Ciba Vision, Air Optix Night \& Day Aqua) soft contact lenses for daily wear (DW) with monthly disposal. 218 healthy myopic (nearsighted) or hyperopic (farsighted) patients with minimal or no astigmatism and no contraindications to DW lens use will be followed for 1 year. The primary outcome is the risk of development of a corneal inflammatory event (CIE) as defined by slit lamp findings and patient symptoms. The main exposure of interest is microbial contamination of study lenses.


Options:
A: Arm Label: 1-Day ACUVUE TruEye contact lens users; Type: N/A; Interventions: Device: narafilcon B daily disposable soft contact lenses | Arm Label: 1-Day ACUVUE MOIST contact lens users; Type: N/A; Interventions: Device: etafilcon A daily disposable soft contact lenses | Intervention Type: DEVICE; Name: narafilcon B daily disposable soft contact lenses; Assigned to Arm(s): 1-Day ACUVUE TruEye contact lens users | Intervention Type: DEVICE; Name: etafilcon A daily disposable soft contact lenses; Assigned to Arm(s): 1-Day ACUVUE MOIST contact lens users
B: Arm Label: Presbyopic group - Low Add; Type: OTHER; Interventions: Device: Etafilcon A, Lotrafilcon B , Senofilcon A | Arm Label: Presbyopic group - Med Add; Type: OTHER; Interventions: Device: Etafilcon A, Lotrafilcon B , Senofilcon A | Arm Label: Presbyopic group - High Add; Type: OTHER; Interventions: Device: Etafilcon A, Lotrafilcon B , Senofilcon A | Arm Label: Non-presbyopic group; Type: OTHER; Interventions: Device: Etafilcon A, Lotrafilcon B , Senofilcon A | Intervention Type: DEVICE; Name: Etafilcon A, Lotrafilcon B , Senofilcon A; Assigned to Arm(s): Non-presbyopic group, Presbyopic group - High Add, Presbyopic group - Low Add, Presbyopic group - Med Add
C: Arm Label: Hyperosmolarity group; Type: EXPERIMENTAL; Interventions: Other: Daily-disposable soft contact lens | Arm Label: Normal osmolarity; Type: EXPERIMENTAL; Interventions: Other: Daily-disposable soft contact lens | Intervention Type: OTHER; Name: Daily-disposable soft contact lens; Assigned to Arm(s): Hyperosmolarity group, Normal osmolarity
D: Arm Label: ReNu Multiplus and lotrafilcon A lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: lotrafilcon A contact lenses, Device: Renu Multiplus | Arm Label: Clear Care solution and lotrafilcon A lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: lotrafilcon A contact lenses, Device: Clear Care | Intervention Type: DEVICE; Name: lotrafilcon A contact lenses; Assigned to Arm(s): Clear Care solution and lotrafilcon A lenses, ReNu Multiplus and lotrafilcon A lenses | Intervention Type: DEVICE; Name: Renu Multiplus; Assigned to Arm(s): ReNu Multiplus and lotrafilcon A lenses | Intervention Type: DEVICE; Name: Clear Care; Assigned to Arm(s): Clear Care solution and lotrafilcon A lenses

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults Ith Type 2 Diabetes
Brief Summary: Peanuts and peanut butter contain high levels of monounsaturated fat (MUFA), arginine, fiber, phytosterols, resveratrol and vitamin E that have the potential to reduce cardiovascular disease (CVD) risk through improved blood glucose control and favorable modification of blood lipids. When substituted for saturated fat in the diet, MUFA may have important metabolic benefits for persons with diabetes. Therefore, the investigators propose to study the effects of a peanut and peanut butter-enriched diet on markers of CVD risk factors in free-living adults with diabetes residing in Southern California. This study's primary clinical outcome will be high-density lipoprotein (HDL) - cholesterol. Secondary outcomes will include additional serum lipids (total cholesterol, low-density lipoprotein (LDL) - cholesterol and triacylglycerol), glucose, HbA1c, and anthropometry (body weight, body composition and waist circumference). This study will provide vital information about the role of peanuts and peanut butter in modulating blood glucose homeostasis and CVD risk factors among adults with diabetes.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts and peanut butter; Assigned to Arm(s): N/A
B: Arm Label: Walnut Ad libitum diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Ad libitum diet | Arm Label: Walnut Calorie Controlled; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Calorie controlled | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Ad libitum diet; Assigned to Arm(s): Walnut Ad libitum diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Calorie controlled; Assigned to Arm(s): Walnut Calorie Controlled
C: Arm Label: Brazil Nuts; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Brazil Nut | Intervention Type: DIETARY_SUPPLEMENT; Name: Brazil Nut; Assigned to Arm(s): Brazil Nuts
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Almond enriched diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat caloric diet | Intervention Type: BEHAVIORAL; Name: Almond enriched diet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat caloric diet; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Controlled Trial for Complementary and Alternative Medicine Treatment of Pregnancy-Related Low Back Pain.
Brief Summary: This study compares three treatments for low back pain that started during pregnancy. The study hypothesizes that exercise, spinal manipulation, and a mind-body technique called neuroemotional technique (NET) equally affect pain intensity and disability associated with pregnancy-related low back pain. The study also hypothesizes that pain intensity and disability levels do not influence maternal heart rate variability (a measure of stress) and intrauterine attachment (a measure of relationship quality). Ten women will additionally provide blood and salivary oxytocin samples during pregnancy and periodically for three months after birth. These women and their babies will also be videotaped playing for 5 minutes at 2 weeks, 6 weeks, and 3 months postpartum.


Options:
A: Arm Label: postural orientations; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: hatha yoga | Arm Label: hatha yoga exercises; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: hatha yoga | Intervention Type: BEHAVIORAL; Name: hatha yoga; Assigned to Arm(s): hatha yoga exercises, postural orientations
B: Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone | Intervention Type: DRUG; Name: Triamcinolone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): B
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Spinal Manipulation; Type: EXPERIMENTAL; Interventions: Procedure: Spinal Manipulation | Arm Label: Neuroemotional technique (NET); Type: EXPERIMENTAL; Interventions: Procedure: Neuroemotional Technique (NET) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: PROCEDURE; Name: Spinal Manipulation; Assigned to Arm(s): Spinal Manipulation | Intervention Type: PROCEDURE; Name: Neuroemotional Technique (NET); Assigned to Arm(s): Neuroemotional technique (NET)
D: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.
Brief Summary: The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group B
B: Arm Label: IPV Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix | Intervention Type: BIOLOGICAL; Name: Poliorix; Assigned to Arm(s): IPV Group
C: Arm Label: Kinrix + M-M-R II + Varivax; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Arm Label: Kinrix + M-M-R II -> Varivax; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Intervention Type: BIOLOGICAL; Name: GSK Biologicals'Kinrix®; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's MMRII; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's Varivax; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM, Biological: Infanrix+Hib | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Infanrix+Hib | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Infanrix+Hib; Assigned to Arm(s): Group A, Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.
Brief Summary: The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.


Options:
A: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
B: Intervention Type: BIOLOGICAL; Name: Inactivated Polio Vaccine given at an accelerated schedule; Assigned to Arm(s): N/A
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM, Biological: Infanrix+Hib | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Infanrix+Hib | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Infanrix+Hib; Assigned to Arm(s): Group A, Group B
D: Arm Label: IPV Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix | Intervention Type: BIOLOGICAL; Name: Poliorix; Assigned to Arm(s): IPV Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Social Skills Training and Standard Treatment Versus Standard Treatment of Children With ADHD - Attention Deficit Hyperactivity Disorder. Attachment Problems Among Children With ADHD
Brief Summary: The primary purpose of the trial is to examine the effect of the combination of social skills training, parental training and standard treatment versus standard treatment in ADHD patients.

The secondary purpose is to examine differences in the effect of the treatment in relation to the different competences of attachment: secure attachment: unsecure dismissing, unsecure preoccupied or disorganized attachment and in the categories; emotional openness, balance of positivity / negativity to attachment figure/s, idealisation of attachment figure/s, dismissal and/or derogation of attachment, the ability of conflict resolution, disorganisation and coherence of the narrative description.

The tertiary purpose of the trial is to examine differences in the effect of the treatment in relation to the degree of parents symptoms of ADHD.


Options:
A: Arm Label: CBT group; Type: EXPERIMENTAL; Interventions: Behavioral: CBT group | Arm Label: Psychopharmacological treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Psychopharmacological treatment | Intervention Type: DRUG; Name: Psychopharmacological treatment; Assigned to Arm(s): Psychopharmacological treatment | Intervention Type: BEHAVIORAL; Name: CBT group; Assigned to Arm(s): CBT group
B: Arm Label: Combined therapy; Type: EXPERIMENTAL; Interventions: Drug: atomoxetine, Behavioral: Behavior Modification Therapy | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): Combined therapy, Drug therapy | Intervention Type: BEHAVIORAL; Name: Behavior Modification Therapy; Assigned to Arm(s): Combined therapy
C: Arm Label: Social sk. tr., parent tr.,standard tr.; Type: EXPERIMENTAL; Interventions: Behavioral: Social skills training, parental tr. and standard tr. | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Social skills training, parental tr. and standard tr.; Assigned to Arm(s): Social sk. tr., parent tr.,standard tr. | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment
D: Arm Label: Executive function training; Type: EXPERIMENTAL; Interventions: Behavioral: A randomized controlled study of Executive Function training for children with ADHD | Intervention Type: BEHAVIORAL; Name: A randomized controlled study of Executive Function training for children with ADHD; Assigned to Arm(s): Executive function training

Answer: C